TME Pharma N.V. (0N6A) Stock Statistics & Valuation Metrics

TME Pharma N.V. has a market cap or net worth of €7.94M. The enterprise value is €5.89M.

TME Pharma N.V. has 94,186,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

TME Pharma N.V.’s return on equity (ROE) is 22.91 and return on invested capital (ROIC) is -645.15%.

The current PE Ratio of TME Pharma N.V. is -0.17. TME Pharma N.V.’s PEG ratio is <0.01.

In the last 12 months, TME Pharma N.V. had revenue of 17.00K and earned -6.74M in profits. Earnings per share was -1.34.

In the last 12 months, operating cash flow was -2.74M and capital expenditures -4.00K, giving a free cash flow of -2.74M billion.

TME Pharma N.V. pays an annual dividend of ―, resulting in a dividend yield of ―

TME Pharma N.V. upcoming earnings date is Oct 17, 2025, TBA Not Confirmed.

TME Pharma N.V. as a current ratio of 0.86, with Debt / Equity ratio of -321.23%

In the past 12 months, TME Pharma N.V. has paid 2.00K in taxes.

TME Pharma N.V. EV to EBITDA ratio is -0.01, with an EV/FCF ratio of -0.01.

TME Pharma N.V. has €2.70M in cash and marketable securities with €5.00K in debt, giving a net cash position of -€2.70M billion.

Gross margin is 0.00%, with operating margin of -33082.35%, and net profit margin of -39623.53%.

The average price target for TME Pharma N.V. is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy